10:22 AM EDT, 06/25/2024 (MT Newswires) -- Tempus AI ( TEM ) said Tuesday it is launching a collaboration with United Therapeutics ( UTHR ) under which Tempus will develop artificial intelligence-backed medical device software to detect people at risk of having pulmonary hypertension.

Financial details of the collaboration weren't disclosed.

Tempus said it built an algorithm that analyzes the results of electrocardiograms to identify people at risk of the disease.

The algorithm will be deployed at participating medical centers, Tempus said, adding doctors will assess its ability to detect patients at risk.

Tempus and United Therapeutics ( UTHR ) will collaborate on the study to investigate the clinical impact of the technology, Tempus said.

Tempus also said it plans to engage with the US Food and Drug Administration to align on regulatory requirements and the FDA's expectations for validation of the algorithm.

Price: 23.69, Change: -1.62, Percent Change: -6.40